Rezpegaldesleukin

瑞培仑白介素-2

Report date: 2026/04/03 20:03:44

Base Information

Drug NameRezpegaldesleukin
Drug Alias NameNKTR-358LY-3471851
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionRegulatory T-lymphocytes stimulantsInterleukin-2 receptor modulators
TargetsInterleukin-2 receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 1PsoriasisAlopecia Areata +[6
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[29
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesNektar Therapeutics
China Registration ClassN/A

Develop Information

Active IndicationsDiabetes Mellitus, Type 1PsoriasisAlopecia Areata +[5
Inactive IndicationsColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksN/A